{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-eu-ctr-ctis-submissions-and-lifecycle-management”
},
“headline”: “SOP for EU CTR/CTIS Submissions and Lifecycle Management”,
“description”: “This SOP describes procedures for managing clinical trial submissions and lifecycle activities under the EU Clinical Trials Regulation (CTR) and the Clinical Trials Information System (CTIS). It covers sponsor and CRO responsibilities, substantial modifications, results submission, and compliance with EMA transparency requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EU CTR/CTIS Submissions and Lifecycle Management

Purpose

The purpose of this SOP is to outline procedures for submission and lifecycle management of clinical trials under the European Union Clinical Trials Regulation (EU CTR 536/2014) via the Clinical Trials Information System (CTIS). This ensures regulatory compliance, transparency, and harmonized trial management across EU member states.

Scope

This SOP applies to sponsors, CROs, regulatory affairs personnel, and QA staff involved in EU CTR submissions. It covers initial trial application, substantial modifications, ongoing trial updates, results posting, transparency compliance, and inspection readiness under EMA oversight.

Responsibilities

• Sponsor: Ensures timely preparation and submission of CTR applications and lifecycle documents.
• CRO: Supports regulatory submission preparation, translation management, and document upload in CTIS.
• Regulatory Affairs: Reviews and submits CTIS entries, manages communications with NCAs and Ethics Committees.
• QA: Audits submission processes, verifies document integrity, and ensures readiness for EMA inspections.
• Investigator: Provides site-level documentation and ensures consistency with CTR requirements.

Accountability

The Sponsor’s Regulatory Affairs Lead is accountable for all EU CTR/CTIS submissions and lifecycle management activities. CROs share accountability for delegated responsibilities.

Procedure

1. Initial Clinical Trial Application
1.1 Prepare CTA dossier according to EU CTR Annex I.
1.2 Upload documents (protocol, IMPD, IB, informed consent, etc.) in CTIS.
1.3 Record submission in EU CTR Application Log (Annexure-1).

2. Validation and Assessment
2.1 Monitor validation requests from Member States.
2.2 Respond to requests within required timelines (10/12 days).
2.3 Document in Validation Response Log (Annexure-2).

3. Substantial Modifications
3.1 Identify modifications requiring resubmission (e.g., protocol amendments, safety changes).
3.2 Submit through CTIS with justification.
3.3 Record in Modification Log (Annexure-3).

4. Ongoing Trial Updates
4.1 Update recruitment status, investigator sites, and safety reports in CTIS.
4.2 Document in Ongoing Update Log (Annexure-4).

5. Results Posting
5.1 Submit summary results within 12 months of trial completion.
5.2 Pediatric trials must be posted within 6 months.
5.3 Record in Results Submission Log (Annexure-5).

6. Transparency and Public Disclosure
6.1 Ensure consistency with EMA transparency rules.
6.2 Flag documents requiring confidentiality protection.
6.3 Record in Transparency Log (Annexure-6).

7. Archiving and Inspection Readiness
7.1 Maintain inspection-ready CTIS records.
7.2 Archive all CTR/CTIS documents in TMF.
7.3 Document in Archiving Log (Annexure-7).

Abbreviations

• SOP: Standard Operating Procedure
• EU CTR: European Union Clinical Trials Regulation
• CTIS: Clinical Trials Information System
• CTA: Clinical Trial Application
• EMA: European Medicines Agency
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File

Documents

1. EU CTR Application Log (Annexure-1)
2. Validation Response Log (Annexure-2)
3. Modification Log (Annexure-3)
4. Ongoing Update Log (Annexure-4)
5. Results Submission Log (Annexure-5)
6. Transparency Log (Annexure-6)
7. Archiving Log (Annexure-7)

References

• EMA – Clinical Trials Information System (CTIS)
• EU Clinical Trials Regulation (EU CTR 536/2014)
• ICH GCP – International Standards

Version: 1.0

Approval Section

Annexures

Annexure-1: EU CTR Application Log

Annexure-2: Validation Response Log

Annexure-3: Modification Log

Annexure-4: Ongoing Update Log

Annexure-5: Results Submission Log

Annexure-6: Transparency Log

Annexure-7: Archiving Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-eudravigilance-susar-icsr-submissions-and-follow-ups”
},
“headline”: “SOP for EudraVigilance SUSAR/ICSR Submissions and Follow-Ups”,
“description”: “This SOP outlines the process for submitting and managing SUSARs (Suspected Unexpected Serious Adverse Reactions) and ICSRs (Individual Case Safety Reports) through EudraVigilance. It ensures compliance with EMA pharmacovigilance regulations, timelines, and follow-up obligations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EudraVigilance SUSAR/ICSR Submissions and Follow-Ups

Purpose

The purpose of this SOP is to establish standardized procedures for reporting and managing Suspected Unexpected Serious Adverse Reactions (SUSARs) and Individual Case Safety Reports (ICSRs) through the European Medicines Agency’s (EMA) EudraVigilance system. This ensures compliance with EU Clinical Trials Regulation (CTR), Good Pharmacovigilance Practices (GVP), and applicable EMA guidance.

Scope

This SOP applies to sponsors, investigators, CROs, pharmacovigilance staff, and regulatory affairs personnel involved in EU clinical trials requiring SUSAR/ICSR submissions. It covers electronic submissions, timelines, MedDRA coding, follow-ups, case reconciliation, and inspection readiness.

Responsibilities

• Sponsor: Ensures timely SUSAR and ICSR submissions via EudraVigilance and overall compliance with EMA regulations.
• Investigator: Reports SAEs to sponsor promptly and provides follow-up data for SUSAR assessment.
• CRO: Assists in preparation, validation, and electronic submission of safety reports.
• Pharmacovigilance Team: Manages safety database, ensures MedDRA coding accuracy, and prepares narratives.
• Regulatory Affairs: Oversees submission compliance and communicates with EMA/NCAs.
• QA: Audits safety reporting workflows and ensures inspection readiness.

Accountability

The Sponsor’s Pharmacovigilance Lead is accountable for compliance with EMA SUSAR/ICSR reporting requirements. Investigators are accountable for site-level SAE reporting accuracy.

Procedure

1. SAE Identification
1.1 Investigators report SAEs to sponsor within 24 hours.
1.2 Sponsor evaluates for SUSAR criteria.
1.3 Record in SAE/SUSAR Log (Annexure-1).

2. Case Assessment
2.1 Assess seriousness, causality, and expectedness against reference safety information (RSI).
2.2 Document in SUSAR Assessment Log (Annexure-2).

3. EudraVigilance Submission
3.1 Submit fatal/life-threatening SUSARs within 7 days.
3.2 Submit other SUSARs within 15 days.
3.3 Submit all ICSRs electronically via EudraVigilance.
3.4 Record in EudraVigilance Submission Log (Annexure-3).

4. MedDRA Coding
4.1 Use latest MedDRA version for coding adverse events.
4.2 Record coding validation in MedDRA Coding Log (Annexure-4).

5. Follow-Up Reporting
5.1 Submit follow-up ICSRs with additional information within 15 days.
5.2 Document in Follow-Up Log (Annexure-5).

6. Case Reconciliation
6.1 Perform quarterly reconciliation of EudraVigilance submissions with internal safety database.
6.2 Document in Reconciliation Log (Annexure-6).

7. Inspection Readiness
7.1 Maintain inspection-ready SUSAR/ICSR records.
7.2 Conduct mock inspections documented in Inspection Readiness Log (Annexure-7).

Abbreviations

• SOP: Standard Operating Procedure
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• ICSR: Individual Case Safety Report
• EMA: European Medicines Agency
• CTR: Clinical Trials Regulation
• CRO: Contract Research Organization
• QA: Quality Assurance
• MedDRA: Medical Dictionary for Regulatory Activities
• RSI: Reference Safety Information

Documents

1. SAE/SUSAR Log (Annexure-1)
2. SUSAR Assessment Log (Annexure-2)
3. EudraVigilance Submission Log (Annexure-3)
4. MedDRA Coding Log (Annexure-4)
5. Follow-Up Log (Annexure-5)
6. Reconciliation Log (Annexure-6)
7. Inspection Readiness Log (Annexure-7)

References

• EMA – EudraVigilance
• EU Clinical Trials Regulation (EU CTR 536/2014)
• ICH E2A/E2F Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: SAE/SUSAR Log

Annexure-2: SUSAR Assessment Log

Annexure-3: EudraVigilance Submission Log

Annexure-4: MedDRA Coding Log

Annexure-5: Follow-Up Log

Annexure-6: Reconciliation Log

Annexure-7: Inspection Readiness Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-gdpr-data-subject-rights-access-deletion-restriction-handling”
},
“headline”: “SOP for GDPR Data Subject Rights (Access, Deletion, Restriction) Handling”,
“description”: “This SOP provides detailed procedures for handling GDPR data subject rights in clinical trials, including access, deletion, and restriction requests. It ensures compliance with EMA and EU data protection regulations, while safeguarding subject privacy and maintaining trial integrity.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for GDPR Data Subject Rights (Access, Deletion, Restriction) Handling

Purpose

The purpose of this SOP is to define standardized procedures for handling General Data Protection Regulation (GDPR) data subject rights in clinical trials, specifically access, deletion, and restriction requests. It ensures compliance with EU CTR 536/2014, GDPR Articles 12–23, and EMA guidance while safeguarding subject confidentiality and data integrity.

Scope

This SOP applies to sponsors, investigators, CROs, data protection officers (DPOs), and regulatory affairs staff handling subject personal data in EU clinical trials. It covers receipt, assessment, processing, and documentation of data subject requests relating to access, rectification, erasure, and restriction of processing.

Responsibilities

• Sponsor: Ensures GDPR-compliant handling of all data subject rights requests and maintains oversight of CRO and site practices.
• Investigator: Communicates subject requests to sponsor and ensures local site compliance with GDPR obligations.
• DPO: Oversees GDPR compliance, reviews requests, and advises on legal obligations.
• CRO: Supports sponsors in tracking, responding to, and documenting GDPR requests.
• Regulatory Affairs: Ensures requests and responses align with EMA/CTR timelines and obligations.
• QA: Audits GDPR-related processes and documentation for compliance.

Accountability

The Sponsor’s Data Protection Officer (DPO) is accountable for ensuring GDPR compliance in relation to data subject rights in clinical trials.

Procedure

1. Receipt of Requests
1.1 Accept data subject requests via email, written communication, or verbal notification at sites.
1.2 Record in GDPR Request Log (Annexure-1).

2. Verification of Identity
2.1 Confirm identity of requestor before processing.
2.2 Document verification in Identity Verification Log (Annexure-2).

3. Assessment of Request
3.1 Determine if request relates to access, deletion, or restriction.
3.2 Verify whether trial records can be altered without compromising scientific validity or regulatory obligations.
3.3 Record assessment in GDPR Assessment Log (Annexure-3).

4. Response Timelines
4.1 Provide acknowledgment of request within 7 calendar days.
4.2 Provide formal response within 30 days (extendable to 60 days with justification).
4.3 Document in Response Timeline Log (Annexure-4).

5. Access Requests
5.1 Provide subject with copy of their personal data upon request.
5.2 Ensure sensitive data is redacted where legally necessary.

6. Deletion (Right to Erasure)
6.1 Evaluate if deletion is possible without violating clinical trial obligations (e.g., GCP retention requirements).
6.2 If erasure is not possible, provide justification in writing.
6.3 Record action in Deletion Log (Annexure-5).

7. Restriction of Processing
7.1 Restrict data processing where legally required.
7.2 Maintain data in secure archive until restriction is lifted.
7.3 Document in Restriction Log (Annexure-6).

8. Documentation and Archiving
8.1 Archive all GDPR requests and responses in TMF and ISF.
8.2 Retain documentation for minimum 25 years per EU CTR requirements.

Abbreviations

• SOP: Standard Operating Procedure
• GDPR: General Data Protection Regulation
• DPO: Data Protection Officer
• EMA: European Medicines Agency
• CTR: Clinical Trials Regulation
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. GDPR Request Log (Annexure-1)
2. Identity Verification Log (Annexure-2)
3. GDPR Assessment Log (Annexure-3)
4. Response Timeline Log (Annexure-4)
5. Deletion Log (Annexure-5)
6. Restriction Log (Annexure-6)

References

• GDPR Articles 12–23 – Data Subject Rights
• EU Clinical Trials Regulation (EU CTR 536/2014)
• European Medicines Agency (EMA)
• ICH GCP Ethical Standards

Version: 1.0

Approval Section

Annexures

Annexure-1: GDPR Request Log

Annexure-2: Identity Verification Log

Annexure-3: GDPR Assessment Log

Annexure-4: Response Timeline Log

Annexure-5: Deletion Log

Annexure-6: Restriction Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-eu-imp-device-labelling-annex-13-annex-vi-specifics”
},
“headline”: “SOP for EU IMP/Device Labelling (Annex 13/Annex VI) Specifics”,
“description”: “This SOP outlines EU-specific labelling requirements for Investigational Medicinal Products (IMPs) and devices under Annex 13 and Annex VI. It ensures compliance with EMA regulations, multilingual label requirements, batch control, and inspection readiness in clinical trials.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EU IMP/Device Labelling (Annex 13/Annex VI) Specifics

Purpose

The purpose of this SOP is to define standardized procedures for labelling Investigational Medicinal Products (IMPs) and medical devices in compliance with European Union requirements under Annex 13 of Directive 2001/20/EC and Annex VI of the EU Medical Device Regulation (EU MDR 2017/745). This ensures subject safety, trial integrity, and regulatory compliance.

Scope

This SOP applies to sponsors, packaging and labelling vendors, QA, CROs, and investigators involved in EU clinical trials. It covers IMP and device label content, multilingual translations, expiry date handling, blinding/unblinding, batch-specific labelling, and archiving.

Responsibilities

• Sponsor: Ensures compliance of IMP and device labels with Annex 13/Annex VI and provides approved templates.
• Packaging Vendor: Prints and applies labels as per sponsor’s approved design and regulatory requirements.
• Investigator: Ensures labelled products are stored and dispensed appropriately at site.
• CRO: Oversees vendor activities and supports regulatory submissions of label templates.
• QA: Conducts label verification, audits, and ensures inspection readiness.

Accountability

The Sponsor’s Regulatory Affairs and QA leads are accountable for compliance with EU IMP and device labelling requirements.

Procedure

1. Label Design and Approval
1.1 Draft label templates in accordance with Annex 13 (IMPs) or Annex VI (devices).
1.2 Include mandatory elements: trial reference code, batch/lot number, expiry date, storage conditions, “For Clinical Trial Use Only.”
1.3 Obtain sponsor and QA approval prior to printing.
1.4 Record in Label Template Approval Log (Annexure-1).

2. Multilingual Requirements
2.1 Translate label text into official languages of Member States where trial is conducted.
2.2 Verify translations by certified linguists.
2.3 Document in Translation Verification Log (Annexure-2).

3. Printing and Application
3.1 Print labels with secure, legible fonts and tamper-proof adhesive.
3.2 Apply labels under controlled packaging conditions.
3.3 Document in Label Printing Log (Annexure-3).

4. Batch-Specific Labelling
4.1 Apply batch/lot numbers and expiry dates at packaging stage.
4.2 Maintain traceability in Batch Labelling Log (Annexure-4).

5. Blinding/Unblinding
5.1 For blinded studies, apply labels without disclosing allocation.
5.2 Unblinding procedures must be defined in trial protocol.
5.3 Document in Blinding Control Log (Annexure-5).

6. Quality Control and Verification
6.1 QA verifies label content, alignment, and compliance before release.
6.2 Document verification in Label QC Log (Annexure-6).

7. Archiving
7.1 Archive sample labels, approvals, and batch records in TMF.
7.2 Retain for minimum 25 years per EU CTR requirements.
7.3 Document in Label Archiving Log (Annexure-7).

Abbreviations

• SOP: Standard Operating Procedure
• IMP: Investigational Medicinal Product
• EMA: European Medicines Agency
• EU CTR: Clinical Trials Regulation
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• MDR: Medical Device Regulation

Documents

1. Label Template Approval Log (Annexure-1)
2. Translation Verification Log (Annexure-2)
3. Label Printing Log (Annexure-3)
4. Batch Labelling Log (Annexure-4)
5. Blinding Control Log (Annexure-5)
6. Label QC Log (Annexure-6)
7. Label Archiving Log (Annexure-7)

References

• Annex 13 of Directive 2001/20/EC
• Annex VI of EU MDR 2017/745
• European Medicines Agency (EMA)
• ICH GCP E6(R2)

Version: 1.0

Approval Section

Annexures

Annexure-1: Label Template Approval Log

Annexure-2: Translation Verification Log

Annexure-3: Label Printing Log

Annexure-4: Batch Labelling Log

Annexure-5: Blinding Control Log

Annexure-6: Label QC Log

Annexure-7: Label Archiving Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-paediatric-investigation-plan-pip-obligations-tracking”
},
“headline”: “SOP for Paediatric Investigation Plan (PIP) Obligations Tracking”,
“description”: “This SOP defines procedures for managing and tracking Paediatric Investigation Plan (PIP) obligations in compliance with EMA requirements. It covers PIP preparation, submission, modifications, deferrals, waivers, and regulatory reporting obligations for sponsors and CROs.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Paediatric Investigation Plan (PIP) Obligations Tracking

Purpose

The purpose of this SOP is to establish a standardized process for managing Paediatric Investigation Plan (PIP) obligations as mandated under the European Paediatric Regulation (EC No 1901/2006). This ensures that sponsors comply with EMA requirements for the development and authorization of medicines intended for use in children, including deferrals and waivers.

Scope

This SOP applies to sponsors, CROs, regulatory affairs, clinical development, and QA personnel responsible for paediatric clinical development in the EU. It covers PIP submission, tracking obligations, reporting modifications, monitoring deferrals/waivers, and ensuring readiness for EMA inspections.

Responsibilities

• Sponsor: Prepares, submits, and tracks PIP obligations with EMA and ensures timely reporting.
• Regulatory Affairs: Manages PIP correspondence, submissions, and modifications in CTIS.
• CRO: Supports operationalization of PIP trials and assists with reporting.
• Clinical Development: Aligns trial design with approved PIP requirements.
• QA: Audits PIP compliance and ensures inspection readiness.

Accountability

The Sponsor’s Regulatory Affairs Lead is accountable for PIP compliance and timely fulfilment of obligations.

Procedure

1. PIP Preparation and Submission
1.1 Draft PIP in accordance with EMA requirements.
1.2 Submit via EMA’s Paediatric Committee (PDCO) portal.
1.3 Record submission in PIP Submission Log (Annexure-1).

2. Deferrals and Waivers
2.1 Identify if waiver or deferral applies.
2.2 Obtain formal approval from EMA.
2.3 Record in Waiver/Deferral Log (Annexure-2).

3. Modifications
3.1 Submit modifications for significant changes in study design or timelines.
3.2 Track approvals in PIP Modification Log (Annexure-3).

4. Tracking Obligations
4.1 Monitor timelines for PIP-related milestones.
4.2 Use internal tracking tools for trial execution.
4.3 Record updates in PIP Tracking Log (Annexure-4).

5. Results Reporting
5.1 Submit paediatric study results within required timelines.
5.2 Document in PIP Results Log (Annexure-5).

6. Inspection Readiness
6.1 Maintain inspection-ready records for PIP compliance.
6.2 Archive documentation in TMF.
6.3 Record in PIP Archiving Log (Annexure-6).

Abbreviations

• SOP: Standard Operating Procedure
• PIP: Paediatric Investigation Plan
• EMA: European Medicines Agency
• PDCO: Paediatric Committee
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• CTIS: Clinical Trials Information System

Documents

1. PIP Submission Log (Annexure-1)
2. Waiver/Deferral Log (Annexure-2)
3. PIP Modification Log (Annexure-3)
4. PIP Tracking Log (Annexure-4)
5. PIP Results Log (Annexure-5)
6. PIP Archiving Log (Annexure-6)

References

• EMA – Paediatric Investigation Plans
• Regulation (EC) No 1901/2006 on Medicinal Products for Paediatric Use
• ICH GCP Ethical Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: PIP Submission Log

Annexure-2: Waiver/Deferral Log

Annexure-3: PIP Modification Log

Annexure-4: PIP Tracking Log

Annexure-5: PIP Results Log

Annexure-6: PIP Archiving Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-25-year-minimum-archiving-and-sponsor-responsibility”
},
“headline”: “SOP for 25-Year Minimum Archiving and Sponsor Responsibility”,
“description”: “This SOP outlines procedures for ensuring compliance with EMA and EU CTR requirements on minimum 25-year archiving of clinical trial records. It defines sponsor responsibilities, secure storage standards, premature destruction prevention, and inspection readiness obligations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for 25-Year Minimum Archiving and Sponsor Responsibility

Purpose

The purpose of this SOP is to define requirements and processes for archiving essential clinical trial records for a minimum of 25 years, in compliance with the EU Clinical Trials Regulation (EU CTR 536/2014) and EMA guidance. This SOP ensures sponsor accountability for secure, long-term storage of both paper and electronic records.

Scope

This SOP applies to sponsors, CROs, investigators, and QA personnel involved in archiving of trial master files (TMFs), investigator site files (ISFs), safety records, and essential clinical trial documents. It covers responsibilities, archiving standards, premature destruction prevention, and regulatory inspection readiness.

Responsibilities

• Sponsor: Ensures compliance with 25-year archiving, oversees CROs and sites, and funds secure long-term storage.
• Investigator: Maintains investigator site records and ensures transfer to secure archives.
• CRO: Supports sponsor in TMF/ISF maintenance and vendor oversight.
• QA: Audits archive facilities and processes to ensure compliance.
• Archive Vendor: Provides validated storage with environmental and security controls.

Accountability

The Sponsor is ultimately accountable for 25-year record retention compliance, regardless of delegation to CROs or archive vendors.

Procedure

1. Identification of Essential Records
1.1 Identify documents required for 25-year retention under EU CTR.
1.2 Include TMF, ISF, safety reports, informed consent forms, and regulatory correspondence.
1.3 Record in Essential Documents List (Annexure-1).

2. Secure Archiving
2.1 Store documents in validated archive facilities with environmental monitoring (temperature, humidity).
2.2 Maintain access logs.
2.3 Record in Archive Facility Log (Annexure-2).

3. Electronic Records
3.1 Validate electronic archiving systems with audit trails.
3.2 Perform periodic data integrity checks.
3.3 Record in Electronic Archive Log (Annexure-3).

4. Prevention of Premature Destruction
4.1 Records must not be destroyed before 25 years unless authorized by EMA.
4.2 Maintain Destruction Prevention Log (Annexure-4).

5. Access and Confidentiality
5.1 Limit access to authorized staff only.
5.2 Document in Archive Access Log (Annexure-5).

6. Inspection Readiness
6.1 Maintain archives in inspection-ready condition.
6.2 Conduct periodic mock audits recorded in Archive Audit Log (Annexure-6).

Abbreviations

• SOP: Standard Operating Procedure
• TMF: Trial Master File
• ISF: Investigator Site File
• EMA: European Medicines Agency
• EU CTR: European Union Clinical Trials Regulation
• CRO: Contract Research Organization
• QA: Quality Assurance

Documents

1. Essential Documents List (Annexure-1)
2. Archive Facility Log (Annexure-2)
3. Electronic Archive Log (Annexure-3)
4. Destruction Prevention Log (Annexure-4)
5. Archive Access Log (Annexure-5)
6. Archive Audit Log (Annexure-6)

References

• EU Clinical Trials Regulation (EU CTR 536/2014)
• European Medicines Agency (EMA)
• ICH GCP E6(R2)

Version: 1.0

Approval Section

Annexures

Annexure-1: Essential Documents List

Annexure-2: Archive Facility Log

Annexure-3: Electronic Archive Log

Annexure-4: Destruction Prevention Log

Annexure-5: Archive Access Log

Annexure-6: Archive Audit Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-qp-certification-interface-gcp-gmp-handoff-expectations”
},
“headline”: “SOP for QP Certification Interface (GCP-GMP Handoff Expectations)”,
“description”: “This SOP defines the process of Qualified Person (QP) certification and the GCP-GMP handoff expectations in clinical trials. It ensures IMP batch release, compliance with EU GMP Annex 13, and proper documentation of certification activities for regulatory inspections.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for QP Certification Interface (GCP-GMP Handoff Expectations)

Purpose

The purpose of this SOP is to outline the Qualified Person (QP) certification process and define expectations for the interface between Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) during clinical trial product release. This ensures Investigational Medicinal Product (IMP) batches are certified, documented, and released in compliance with EU GMP Annex 13, EMA guidelines, and EU CTR 536/2014 requirements.

Scope

This SOP applies to sponsors, QPs, manufacturing sites, CROs, and QA staff responsible for manufacturing, packaging, and releasing IMPs for EU clinical trials. It covers certification activities, documentation review, IMP release, and archiving of certification records.

Responsibilities

• Qualified Person (QP): Certifies IMP batches before release to trial sites and ensures compliance with GMP Annex 13.
• Sponsor: Provides QP with necessary GCP trial documentation (protocol, approvals, investigator details).
• Manufacturer: Ensures IMP is manufactured and packaged according to GMP standards.
• CRO: Coordinates between sponsor, QP, and sites for product release and distribution.
• QA: Audits QP certification process and maintains inspection readiness.

Accountability

The Qualified Person (QP) is accountable for certifying IMP batches prior to release. The Sponsor is accountable for ensuring complete documentation and regulatory compliance for GCP-GMP handoff.

Procedure

1. Documentation Preparation
1.1 Sponsor provides QP with the Investigational Medicinal Product Dossier (IMPD), batch records, certificates of analysis (CoA), and clinical trial authorization.
1.2 Record in QP Documentation Log (Annexure-1).

2. Batch Certification
2.1 QP reviews batch manufacturing records for compliance with GMP.
2.2 Certify batch in QP Certification Log (Annexure-2).
2.3 Ensure certification statement is archived in TMF.

3. GCP-GMP Handoff
3.1 Sponsor ensures QP certification is documented before IMP shipment to sites.
3.2 QP communicates certification status to sponsor and CRO.
3.3 Record in Handoff Log (Annexure-3).

4. IMP Release
4.1 Distribute certified IMP to clinical sites only after QP release.
4.2 Maintain traceability in IMP Release Log (Annexure-4).

5. Non-Compliance Handling
5.1 If QP identifies GMP deviations, batch must not be released.
5.2 CAPA plan developed and recorded in Deviation Log (Annexure-5).

6. Archiving
6.1 Archive all certification documents in TMF for minimum 25 years.
6.2 Maintain archive record in Certification Archiving Log (Annexure-6).

Abbreviations

• SOP: Standard Operating Procedure
• QP: Qualified Person
• IMP: Investigational Medicinal Product
• GCP: Good Clinical Practice
• GMP: Good Manufacturing Practice
• EMA: European Medicines Agency
• CTR: Clinical Trials Regulation
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File

Documents

1. QP Documentation Log (Annexure-1)
2. QP Certification Log (Annexure-2)
3. Handoff Log (Annexure-3)
4. IMP Release Log (Annexure-4)
5. Deviation Log (Annexure-5)
6. Certification Archiving Log (Annexure-6)

References

• EU GMP Annex 13 – IMPs
• EU Clinical Trials Regulation (536/2014)
• European Medicines Agency (EMA)
• ICH GCP Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: QP Documentation Log

Annexure-2: QP Certification Log

Annexure-3: Handoff Log

Annexure-4: IMP Release Log

Annexure-5: Deviation Log

Annexure-6: Certification Archiving Log

Revision History

For more SOPs visit: Pharma SOP